Day: March 8, 2022

Entera Bio Reports Financial Results for the Year Ended December 31, 2021

Written by Customer Service on March 8, 2022. Posted in Earnings Releases And Operating Results.

— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral delivery technology platform advances with more indications, inventions, patents, and collaborations —— Company to host conference call and webcast today at 8:30 AM EST — BOSTON and JERUSALEM, March 08, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced financial and operating results for the year ended December 31, 2021, and provided an update on its clinical and pre-clinical programs. 2021 and Recent HighlightsSuccessful End of Phase 2 Meeting with FDA: Entera met with the U.S. Food and Drug Administration (FDA), presented Phase 2 results, and reviewed the development plan of EB613...

Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Written by Customer Service on March 8, 2022. Posted in Earnings Releases And Operating Results.

– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 – – Potential Pathway to NDA Submission for MAT2203 with Confirmatory Data to Come from Cohort 5 of EnACT Trial – – Second in vivo Study of Oral LNC-remdesivir to Commence in March 2022 – – Moving Aggressively into Nucleic Acids with Internal Discovery Programs Initiated with mRNA, DNA and Antisense Oligonucleotides (ASOs) – – $49.6 million at Year-End 2021, Sufficient to Fund Planned Operations Through 2023 – – Management to Host Conference Call Today, Tuesday, March 8th, at 8:30 a.m. ET – BEDMINSTER, N.J., March 08, 2022 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small...

OLAPLEX Reports Fourth Quarter and Fiscal Year 2021 Results

Written by Customer Service on March 8, 2022. Posted in Earnings Releases And Operating Results.

Net Sales grew 79% in the fourth quarter and 112% for the fiscal year to $598 million, exceeding guidanceDiluted EPS for the fiscal year of $0.32 and Adjusted Diluted EPS of $0.40, exceeding guidanceCompany introduces fiscal 2022 outlook SANTA BARBARA, Calif., March 08, 2022 (GLOBE NEWSWIRE) — Olaplex Holdings, Inc. (NASDAQ: OLPX) (“OLAPLEX” or the “Company”), an innovative, science-enabled, technology-driven beauty company, focused on delivering its patent-protected premium hair care products to professional hair salons, retailers, and everyday consumers, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021. Financial Highlights: Fiscal Year 2021 compared to Fiscal Year 2020:Net sales increased 112.0% to $598.4 million;Net sales increased 131% in the United States and increased 91%...

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

Written by Customer Service on March 8, 2022. Posted in Earnings Releases And Operating Results.

License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets Novartis agreement marks second recent major transaction to leverage Voyager’s TRACER technology following October 2021 Pfizer agreement Strengthened leadership with appointment of Al Sandrock, Jr., M.D., Ph.D., to Board of Directors and Board Executive Committee, promotion of Robin Swartz to chief operating officer Cash runway extended into 2024 with $84 million aggregate upfront payments from Novartis and Pfizer transactions Conference call and webcast today at 8:30 a.m. ET CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments...

Brunswick Corporation to Present at Raymond James Conference

Written by Customer Service on March 8, 2022. Posted in Public Companies.

METTAWA, Ill., March 08, 2022 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) Chief Executive Officer David M. Foulkes and Executive Vice President, CFO Ryan Gwillim will present at the Raymond James 43rd Annual Institutional Investor Conference, March 9, at J. W. Marriott Grande Lakes in Orlando, Fla. The presentation will be webcast live at approximately 9:15am EST. The presentation can be accessed at https://kvgo.com/rj-43rd-iic/brunswick-corporation-march-2022. Go to the site at least 15 minutes before the presentation to register, download and install any needed audio software. The audio presentation will be available on the Brunswick site. About Brunswick Headquartered in Mettawa, Ill., Brunswick Corporation’s leading consumer brands include Mercury Marine outboard engines; Mercury MerCruiser sterndrive and inboard...

Gofore Plc: Managers’ transactions – Nylund

Written by Customer Service on March 8, 2022. Posted in Public Companies.

GOFORE PLC MANAGERS’ TRANSACTIONS 8 MARCH 2022 AT 13:00 Managers’ Transactions – Nylund Person subject to the notification requirementName: Mikael NylundPosition: Chief Executive Officer Issuer: Gofore OyjLEI: 743700JIW1LAUZDH9012Notification type: INITIAL NOTIFICATIONReference number: 11076/4/4____________________________________________   Transaction date: 2022-03-07Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000283130Nature of the transaction: DISPOSAL Transaction details(1): Volume: 17115 Unit price: 22.2 EURAggregated transactions(1): Volume: 17115 Volume weighted average price: 22.2 EUR Further enquiries:  Teppo Talvinko, CFO, Gofore Plc   tel. +358 40 715 3660   teppo.talvinko@gofore.com  Gofore Plc is a digital transformation consultancy with over 1000 impact-driven employees across Finland, Germany,...

Gofore Plc: Managers’ transactions – Virtanen

Written by Customer Service on March 8, 2022. Posted in Public Companies.

GOFORE PLC MANAGERS’ TRANSACTIONS 8 MARCH 2022 AT 13:00 Managers’ Transactions – Virtanen Person subject to the notification requirementName: Juha VirtanenPosition: Other senior manager Issuer: Gofore OyjLEI: 743700JIW1LAUZDH9012Notification type: INITIAL NOTIFICATIONReference number: 11079/4/4____________________________________________   Transaction date: 2022-03-07Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000283130Nature of the transaction: DISPOSAL Transaction details(1): Volume: 17003 Unit price: 22.2 EURAggregated transactions(1): Volume: 17003 Volume weighted average price: 22.2 EUR Further enquiries:  Teppo Talvinko, CFO, Gofore Plc   tel. +358 40 715 3660   teppo.talvinko@gofore.com  Gofore Plc is a digital transformation consultancy with over 1000 impact-driven employees across Finland,...

Gofore Plc: Managers’ transactions – Kirjavainen

Written by Customer Service on March 8, 2022. Posted in Public Companies.

GOFORE PLC MANAGERS’ TRANSACTIONS 8 MARCH 2022 AT 13:00 Managers’ Transactions – Kirjavainen Person subject to the notification requirementName: EMK Invest OyPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Elja KirjavainenPosition: Other senior manager Issuer: Gofore OyjLEI: 743700JIW1LAUZDH9012Notification type: INITIAL NOTIFICATIONReference number: 11073/5/4____________________________________________   Transaction date: 2022-03-07Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000283130Nature of the transaction: DISPOSAL Transaction details(1): Volume: 11882 Unit price: 22.2 EURAggregated transactions(1): Volume: 11882 Volume weighted average price: 22.2 EUR Further enquiries:  Teppo Talvinko, CFO, Gofore Plc   tel. +358 40 715 3660   ...

DMG Announces Preliminary Q1 2021-2 Revenue Guidance of $13.5 – $14 Million

Written by Customer Service on March 8, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB US: DMGGF) (FRANKFURT: 6AX) (“DMG” or the “Company”), a vertically integrated blockchain and cryptocurrency technology company, has released select preliminary revenue guidance for the three-month period ending Dec. 31, 2021 (first quarter). All financial information in this press release is unaudited and reported in Canadian dollars unless otherwise indicated. With the receipt of additional crypto miners throughout Q1, DMG’s mining capacity increased resulting in expected consolidated revenue for Q1 2021-2 to be in the range of $13.5-14 million, compared with $3.5 – $4 million in Q4 2021, an approximately 260% increase quarter over quarter. The Company expects to file its interim financial statements and accompanying...

Tritium to Participate in Spring Investor Conferences and Events

Written by Customer Service on March 8, 2022. Posted in Public Companies.

BRISBANE, Australia, March 08, 2022 (GLOBE NEWSWIRE) — Tritium DCFC Limited (“Tritium”) (NASDAQ: DCFC), today announced that management is expected to attend, present and meet with investors at the following conferences and events:34th Annual ROTH Conference, Dana Point, CA (in-person), March 14-15, 2022 Piper Sandler Virtual EV Charging Day, April 5, 2022 CGS-CIMB/Raymond James Technology and EV Conference, April 8, 2022 Advanced Clean Transportation (“ACT”) Expo, Long Beach, CA (in-person), May 10-12, 2022Tritium’s most recent presentation will be made available on the investors section of its website, at tritiumcharging.com. About Tritium Founded in 2001, Tritium (NASDAQ: DCFC; DCFCW) designs and manufactures proprietary hardware and software to create advanced and reliable direct current (“DC”) fast chargers for electric...

Day: March 8, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals